Wall Street analysts expect Menlo Therapeutics Inc (NASDAQ:MNLO) to report $2.04 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Menlo Therapeutics’ earnings. The highest sales estimate is $2.40 million and the lowest is $1.72 million. The business is scheduled to issue its next quarterly earnings report on Thursday, August 6th.

According to Zacks, analysts expect that Menlo Therapeutics will report full year sales of $16.08 million for the current fiscal year, with estimates ranging from $13.60 million to $18.64 million. For the next fiscal year, analysts forecast that the firm will report sales of $80.38 million, with estimates ranging from $77.10 million to $85.84 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Menlo Therapeutics.

Menlo Therapeutics (NASDAQ:MNLO) last issued its earnings results on Monday, May 11th. The company reported ($0.95) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.41). The business had revenue of $1.75 million for the quarter, compared to analyst estimates of $2.21 million.

MNLO has been the topic of a number of research analyst reports. Bank of America initiated coverage on shares of Menlo Therapeutics in a research note on Wednesday, March 11th. They issued a “buy” rating and a $8.00 price target on the stock. Northland Securities boosted their price target on shares of Menlo Therapeutics from $3.50 to $6.00 and gave the company an “outperform” rating in a research note on Monday, June 1st. HC Wainwright boosted their price target on shares of Menlo Therapeutics from $2.50 to $3.50 and gave the company a “buy” rating in a research note on Monday, June 1st. Zacks Investment Research cut shares of Menlo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 9th. Finally, BidaskClub cut shares of Menlo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Menlo Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $4.50.

Shares of Menlo Therapeutics stock traded down $0.04 on Wednesday, reaching $1.65. The company had a trading volume of 3,349,800 shares, compared to its average volume of 3,070,906. The firm’s 50 day moving average price is $2.08 and its two-hundred day moving average price is $3.32. The firm has a market cap of $283.28 million, a PE ratio of -0.52 and a beta of 1.16. Menlo Therapeutics has a 52-week low of $1.00 and a 52-week high of $7.48. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.68 and a current ratio of 1.74.

In other Menlo Therapeutics news, major shareholder Perceptive Advisors Llc bought 2,702,702 shares of the stock in a transaction on Tuesday, June 9th. The shares were bought at an average price of $1.85 per share, with a total value of $4,999,998.70. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 2.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in MNLO. Nations Financial Group Inc. IA ADV acquired a new position in shares of Menlo Therapeutics during the first quarter worth approximately $27,000. Wetherby Asset Management Inc. bought a new stake in shares of Menlo Therapeutics during the first quarter valued at approximately $29,000. Grace Capital bought a new stake in shares of Menlo Therapeutics during the first quarter valued at approximately $32,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Menlo Therapeutics during the first quarter valued at approximately $32,000. Finally, Nisa Investment Advisors LLC bought a new stake in shares of Menlo Therapeutics during the first quarter valued at approximately $36,000. Institutional investors and hedge funds own 25.46% of the company’s stock.

Menlo Therapeutics Company Profile

Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.

Further Reading: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Menlo Therapeutics (NASDAQ:MNLO)

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.